(Q36548668)

14 August 2017

1 reference

title

Safety of etanercept in psoriasis: a critical review (English)

1 reference

14 August 2017

author name string

Jose L Sánchez Carazo

series ordinal

1

1 reference

14 August 2017

Laura Mahiques Santos

series ordinal

2

1 reference

14 August 2017

Vicente Oliver Martinez

series ordinal

3

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

29

1 reference

14 August 2017

issue

8

1 reference

14 August 2017

page(s)

675-685

1 reference

Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.

14 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200629080-00004

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

12 December 2020

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

1 reference

12 December 2020

1 reference

12 December 2020

Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report

1 reference

12 December 2020

Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?

1 reference

12 December 2020

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

1 reference

12 December 2020

Combining traditional agents and biologics for the treatment of psoriasis

1 reference

12 December 2020

Etanercept and demyelinating disease in a patient with psoriasis

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

1 reference

12 December 2020

Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study

1 reference

12 December 2020

Etanercept monotherapy in patients with psoriasis: a summary of safety, based on an integrated multistudy database

1 reference

12 December 2020

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

1 reference

12 December 2020

An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis

1 reference

12 December 2020

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

1 reference

12 December 2020

Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment.

1 reference

12 December 2020

Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept

1 reference

12 December 2020

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

12 December 2020

Infliximab for psoriasis

1 reference

12 December 2020

Etanercept and urticaria in patients with juvenile idiopathic arthritis.

1 reference

12 December 2020

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

1 reference

12 December 2020

Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group

1 reference

12 December 2020

Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden

1 reference

12 December 2020

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

1 reference

12 December 2020

Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments

1 reference

12 December 2020

Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study.

1 reference

12 December 2020

A novel targeted T-cell modulator, efalizumab, for plaque psoriasis

1 reference

12 December 2020

Drug-induced systemic lupus erythematosus associated with etanercept therapy

1 reference

12 December 2020

Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data

1 reference

12 December 2020

Etanercept-induced subacute cutaneous lupus erythematosus

1 reference

12 December 2020

The pathogenesis of psoriasis: immunological facts and speculations

1 reference

12 December 2020

An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.

1 reference

12 December 2020

The immunologic basis for the treatment of psoriasis with new biologic agents

1 reference

12 December 2020

Experience with etanercept in an academic medical center: are infection rates increased?

1 reference

12 December 2020

Leukocytoclastic vasculitis due to etanercept

1 reference

12 December 2020

Plasma cytokine parameters and mortality in patients with chronic heart failure

1 reference

12 December 2020

Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis

1 reference

12 December 2020

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

1 reference

12 December 2020

Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies

1 reference

12 December 2020

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

12 December 2020

How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH

1 reference

12 December 2020

Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Reactive oxygen species induce cardiomyocyte apoptosis partly through TNF-alpha

1 reference

12 December 2020

Tumor necrosis factor identified in multiple sclerosis brain

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

12 December 2020

Anti-TNF therapy and malignancy - a critical review

1 reference

12 December 2020

A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

Etanercept therapy improves symptoms and allows tapering of other medications in children and adolescents with moderate to severe psoriasis

1 reference

12 December 2020

Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study

1 reference

12 December 2020

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

12 December 2020

TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis.

1 reference

12 December 2020

The tumor necrosis factor ligand and receptor families.

1 reference

12 December 2020

Infliximab monotherapy provides rapid and sustained benefit for plaque-type psoriasis

1 reference

12 December 2020

Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis

1 reference

12 December 2020

Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart

1 reference

12 December 2020

Development and use of alefacept to treat psoriasis

1 reference

12 December 2020

Association between Tumor Necrosis Factor-α and Disease Progression in Patients with Multiple Sclerosis

1 reference

12 December 2020

Autoimmune skin rashes associated with etanercept for rheumatoid arthritis

1 reference

12 December 2020

Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis

1 reference

12 December 2020

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

1 reference

12 December 2020

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

1 reference

12 December 2020

Efalizumab: an overview

1 reference

12 December 2020

Psoriasis, its treatment, and cancer in a cohort of Finnish patients

1 reference

12 December 2020

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

1 reference

12 December 2020

Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure

1 reference

12 December 2020

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

1 reference

12 December 2020

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

1 reference

12 December 2020

Safety overview of new disease-modifying antirheumatic drugs

1 reference

12 December 2020

Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein.

1 reference

12 December 2020

Etanercept: An overview

1 reference

12 December 2020

Etanercept for the treatment of psoriasis and psoriatic arthritis

1 reference

12 December 2020

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

1 reference

12 December 2020

10.2165/00002018-200629080-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

14 August 2017

1044558426

0 references

1 reference